SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Criteria for identification of advanced Parkinson's disease: the results of the Italian subgroup of OBSERVE-PD observational study.

Stefani, A; Tessitore, A; Tambasco, N; Cossu, G; Ceravolo, MG; Defazio, G; Morgante, F; Ramat, S; Melzi, G; Gualberti, G; et al. Stefani, A; Tessitore, A; Tambasco, N; Cossu, G; Ceravolo, MG; Defazio, G; Morgante, F; Ramat, S; Melzi, G; Gualberti, G; Merolla, R; Onuk, K; Lopiano, L (2022) Criteria for identification of advanced Parkinson's disease: the results of the Italian subgroup of OBSERVE-PD observational study. BMC Neurol, 22 (1). p. 41. ISSN 1471-2377 https://doi.org/10.1186/s12883-022-02554-z
SGUL Authors: Morgante, Francesca

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

BACKGROUND: Frequency of Advanced Parkinson's Disease (APD) and its clinical characteristics are still not well defined. Here, we aimed to assess APD prevalence in the Italian OBSERVE-PD cohort, as well as treatment eligibility to device-aided therapies (DAT), and to compare the APD clinical judgment with the established Delphi criteria. METHODS: This sub-group analysis of the OBSERVE-PD study was performed on patients enrolled by 9 Movement Disorders centers in Italy. Motor and non-motor symptoms, PD characteristics, activities of daily living, and quality of life were assessed. Patient eligibility for DAT, response to current PD treatments, referral process, and the concordance between APD physician's judgment and Delphi criteria were also assessed. RESULTS: According to physician's judgment, 60 out of 140 patients (43%) had APD. The correlation between physician's judgment and the overall APD Delphi criteria was substantial (K = 0.743; 95%CI 0.633-0.853), mainly driven by a discrete concordance found for the presence of ≥ 2 h of daily OFF time, presence of troublesome dyskinesia, ≥ 5 times daily oral levodopa dosing, and activities of daily living limitation. Forty-four (73%) APD patients were considered eligible to DAT but only 18 of them (41%) used these therapies, while most patients, independently from their eligibility, continued to use 3-5 oral daily medications, due to fear of invasive solutions and need to have a longer time to decide. CONCLUSION: APD was frequent in the Italian OBSERVE-PD population. DAT in the eligible APD population proved to be underused, in spite of unsatisfactory symptoms control with oral medications in 67% of patients.

Item Type: Article
Additional Information: © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Keywords: Advanced Parkinson’s disease, Device-aided treatment, Quality of life, Activities of Daily Living, Antiparkinson Agents, Humans, Italy, Parkinson Disease, Quality of Life, Advanced Parkinson's disease, Device-aided treatment, Quality of life, Neurology & Neurosurgery, 1109 Neurosciences, 1702 Cognitive Sciences
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: BMC Neurol
ISSN: 1471-2377
Language: eng
Dates:
DateEvent
28 January 2022Published
9 November 2021Accepted
Publisher License: Creative Commons: Attribution 4.0
PubMed ID: 35090406
Web of Science ID: WOS:000749227600001
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/114108
Publisher's version: https://doi.org/10.1186/s12883-022-02554-z

Actions (login required)

Edit Item Edit Item